昭衍新药 (603127.SH)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

财务摘要(单季度)(昭衍新药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年第三季度2024年第二季度2024年第一季度2023年第四季度2023年第三季度2023年第二季度2023年第一季度
单季度财务指标:
 单季度销售毛利率(%) 22.0029.0033.0040.0043.0040.0052.00
 单季度销售净利率(%) 20.0019.00-84.008.0041.00-15.0051.00
 单季度净资产收益率ROE(%) 1.001.00-3.001.003.00-1.002.00
 单季度总资产净利率ROA(%) 1.001.00-3.001.002.00-1.002.00
单季度财务摘要:
 单季度营业总收入(元) 485,799,506.00524,547,440.00324,809,104.00789,407,018.00575,002,491.00642,691,277.00369,386,011.00
 单季度营业总成本(元) 474,671,792.00459,767,812.00293,294,647.00517,173,055.00390,640,555.00451,385,274.00262,811,341.00
 单季度营业收入(元) 485,799,506.00524,547,440.00324,809,104.00789,407,018.00575,002,491.00642,691,277.00369,386,011.00
 单季度营业利润(元) 107,493,728.00115,853,533.00-293,008,275.00115,011,381.00275,245,834.00-97,530,581.00214,369,687.00
 单季度利润总额(元) 107,458,838.00115,778,908.00-293,130,016.00114,965,257.00275,049,509.00-97,393,252.00214,328,924.00
 单季度净利润(元) 97,994,306.00101,125,287.00-273,363,603.0065,355,559.00236,688,832.00-98,201,908.00187,710,079.00
 单季度归属母公司股东的净利润(元) 99,435,566.00102,479,834.00-272,222,475.0069,394,207.00236,971,205.00-97,132,501.00187,759,655.00
 单季度经营活动产生的现金流量(元) 34,609,066.0037,763,124.00119,953,519.00174,434,920.00202,230,470.00259,877,932.00-13,668,184.00
 单季度投资活动产生的现金流量(元) -204,378,807.00-678,109,661.00-67,562,299.00-178,281,706.00-94,841,046.00-148,782,923.00106,476,213.00
 单季度筹资活动产生的现金流量(元) -141,577,836.00-69,321,892.00-37,928,364.00-28,388,699.00-239,686,577.00-68,750,269.00-24,852,352.00
 单季度现金及现金等价物净增加(元) -318,070,633.00-707,119,011.0011,667,128.00-37,627,769.00-136,274,311.0066,397,218.0061,682,309.00

前瞻产业研究院